<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139714">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124382</url>
  </required_header>
  <id_info>
    <org_study_id>CHIRPEDMG2012</org_study_id>
    <nct_id>NCT02124382</nct_id>
  </id_info>
  <brief_title>Living Donor Liver Transplantation in Children</brief_title>
  <official_title>Living Donor Liver Transplantation in Children: Surgical and Immunological Results in 250 Recipients at Université Catholique de Louvain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the outcome of pediatric living donor liver transplantation (LDLT) regarding portal
      vein reconstruction, ABO-compatibility and impact of maternal donation on graft acceptance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data from 250 pediatric LDLT recipients (and their donors), transplanted at Cliniques
      universitaires Saint-Luc between July 1993 and June 2012, were collected retrospectively
      using electronic data files. Results were analysed according to ABO matching and portal vein
      complications. Uni- and multi-variate analysis was used to study the impact of
      immunosuppression, gender match and maternal donation on acute rejection rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kaplan-Meier</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Portal vein complications</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Graft rejection free survival</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Pediatric Liver Transplanted Recipients</condition>
  <condition>Healthy Donors</condition>
  <eligibility>
    <study_pop>
      <textblock>
        250 pediatric living donor liver transplant recipients 250 corresponding adult living
        donors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children receiving a living donor liver transplant

          -  Adult living donors

        Exclusion Criteria:

          -  No one
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>57 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Reding, Md-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver failure</keyword>
  <keyword>liver malignancy</keyword>
  <keyword>metabolic diseases</keyword>
  <keyword>Pediatric liver transplanted recipients and their healthy donors</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
